Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03821376 · ClinicalTrials.gov registry record · Phase 4
Correlation of Renal Mass Pathologic Grade and Contrast Enhanced Ultrasound (CEUS)
A Phase 4 study, sponsored by Indiana University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
NCT03821376 is a Phase 4 study that was terminated before completion, run by Indiana University. The registered enrollment target is 12 participants.
The verdict
NCT03821376, a Phase 4 study, was terminated before completion, sponsored by Indiana University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
Study Summary
Patients with renal lesions suspicious for renal cell carcinoma (RCC) have a variety of different treatment pathways available to them. Imaging surveillance is being used frequently on smaller renal masses, and radiologists are being asked to biopsy more renal lesions to better guide decision making by urology. This is in large part due to the pathologic grade of renal masses having been shown to correlate with patient outcomes. The World Health Organization (WHO) or Fuhrman grade is the standard grading scale used by pathologists for RCC. The goal of this study will be to correlate contrast enhanced ultrasound findings with the pathologic grade of RCC. Specifically, the investigators hypothesize that tumors with different pathologic grades will show different patterns of qualitative enhancement, as well as different perfusion kinetics.
Interventions
- DRUG Contrast enhanced ultrasound with Lumason
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2019-07-16 |
| Est. Completion | 2021-09-21 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03821376
The ClinicalTrials.gov registry entry for NCT03821376 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Contrast enhanced ultrasound with Lumason is the first listed.
NCT03821376 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03821376 about?
NCT03821376 is a clinical study titled "Correlation of Renal Mass Pathologic Grade and Contrast Enhanced Ultrasound (CEUS)". Patients with renal lesions suspicious for renal cell carcinoma (RCC) have a variety of different treatment pathways available to them. Imaging surveillance is being used frequently on smaller renal masses, and radiologists are being asked to biopsy more renal lesions to better guide decision making...
What is the current status of trial NCT03821376?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2019-07-16. Estimated completion is 2021-09-21.
What interventions are being tested in trial NCT03821376?
The interventions under investigation include: Contrast enhanced ultrasound with Lumason (DRUG).
Who is sponsoring clinical trial NCT03821376?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.